Table 2 The incidence rate and relative risk of MACE in SLE patients and the general population.

From: Increased cardiovascular risk in Korean patients with systemic lupus erythematosus: a population-based cohort study

 

Observational period (PYs)

No. of cases

Incidence rate (n/1000 PYs)

Crude IRR (95% CI)

Adjusted IRR (95% CI)*

All patients

 SLE patients

43,579

178

4.08

3.14 (2.59, 3.82)

2.40 (1.88, 3.05)

 General population

181,907

237

1.30

Ref

Ref

Age (years)

 18–39

  SLE patients

23,149

51

2.20

16.16 (8.79, 29.72)

11.70 (5.95, 23.01)**

  General population

95,373

13

0.14

Ref

Ref

 40–49

  SLE patients

10,196

39

3.83

5.37 (3.34, 8.64)

4.00 (2.26, 7.11)

  General population

42,105

30

0.71

Ref

Ref

 50–59

  SLE patients

6548

44

6.72

3.27 (2.21, 4.86)

2.77 (1.72, 4.45)

  General population

27,827

57

2.05

Ref

Ref

 60–79

  SLE patients

3685

44

11.94

1.45 (1.03, 2.03)

1.27 (0.85, 1.90)

  General population

16,602

137

8.25

Ref

Ref

Gender

 Female

  SLE patients

39,007

135

3.46

3.06 (2.45, 3.83)

2.36 (1.79, 3.12)

  General population

161,862

183

1.13

 

Ref

 Male

  SLE patients

4572

43

9.41

3.49 (1.25, 5.21)

2.50 (1.50, 4.17)

  General population

20,045

54

2.69

Ref

Ref

  1. PY person-year, CI confidence interval, IRR incidence rate ratio, MACE major adverse cardiovascular events.
  2. *Adjusted for income, comorbidities (HTN, DM, and hyperlipidaemia), and medication (NSAIDs and glucocorticoids).
  3. **Adjusted for income, comorbidities (HTN, and hyperlipidaemia), and medication (NSAIDs and glucocorticoids), the variable for DM was excluded from the adjusted analysis due to a poor fit.
Back to article page